Evidence map›Paper›PMID 38187779›Full record

ArticlebioRxiv : the preprint server for biology2023

Human disease-specific cell signatures in non-lesional tissue in Multiple Sclerosis detected by single-cell and spatial transcriptomics.

Matti Lam, Dylan Lee, Ivy Kosater, Anthony Khairallah, Mariko Taga, Ya Zhang, Masashi Fujita, Sukriti Nag, David A Bennett, Philip De Jager and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Matti LamCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.ORCID 0000-0002-1853-4209
Dylan LeeCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Ivy KosaterCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Anthony KhairallahCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Mariko TagaCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Ya ZhangCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Masashi FujitaCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Sukriti NagRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL.
Philip De JagerCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Vilas MenonCenter for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center.
Columbia University Irving Medical Center · USRush University Medical Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Elucidating changes in astrocyte subpopulations associated with resistance to Alzheimers Disease pathology in multi-ethnic cohortsR01AG066831 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MENON, VILAS · 2020 to 2024
$3.3M
Identifying shared and distinct cell type vulnerability across neurological diseases.R21AG075754 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AL DALAHMAH, OSAMA, GOLDMAN, JAMES · 2022 to 2022
$446k
NCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013696NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG066831NIA NIH HHS R21 AG075754
6 · The paper itself

Abstract

Recent investigations of cell type changes in Multiple Sclerosis (MS) using single-cell profiling methods have focused on active lesional and peri-lesional brain tissue, and have implicated a number of peripheral and central nervous system cell types. However, an important question is the extent to which so-called "normal-appearing" non-lesional tissue in individuals with MS accumulate changes over the lifespan. Here, we compared post-mortem non-lesional brain tissue from donors with a pathological or clinical diagnosis of MS from the Religious Orders Study or Rush Memory and Aging Project (ROSMAP) cohorts to age- and sex-matched brains from persons without MS (controls). We profiled three brain regions using single-nucleus RNA-seq: dorsolateral prefrontal cortex (DLPFC), normal appearing white matter (NAWM) and the pulvinar in thalamus (PULV), from 15 control individuals, 8 individuals with MS, and 5 individuals with other detrimental pathologies accompanied by demyelination, resulting in a total of 78 samples. We identified region- and cell type-specific differences in non-lesional samples from individuals diagnosed with MS and/or exhibiting secondary demyelination with other neurological conditions, as compared to control donors. These differences included lower proportions of oligodendrocytes with expression of myelination related genes MOBP, MBP, PLP1, as well as higher proportions of CRYAB+ oligodendrocytes in all three brain regions. Among microglial signatures, we identified subgroups that were higher in both demyelination (TMEM163+/ERC2+), as well as those that were specifically higher in MS donors (HIF1A+/SPP1+) and specifically in donors with secondary demyelination (SOCS6+/MYO1E+), in both white and grey matter. To validate our findings, we generated Visium spatial transcriptomics data on matched tissue from 13 donors, and recapitulated our observations of gene expression differences in oligodendrocytes and microglia. Finally, we show that some of the differences observed between control and MS donors in NAWM mirror those previously reported between control WM and active lesions in MS donors. Overall, our investigation sheds additional light on cell type- and disease-specific differences present even in non-lesional white and grey matter tissue, highlighting widespread cellular signatures that may be associated with downstream pathological changes.

Identifiers

PMID38187779
PMCPMC10769298
OpenAlexW4389989997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.